What is 3DBio Therapeutics?
3DBio Therapeutics is a pioneering biologics and bioprinting company dedicated to advancing regenerative medicine. The company specializes in the manufacturing of living tissues, engineered specifically for individual patients to facilitate the replacement of biological parts. Its proprietary technology platform encompasses a novel 3D-bioprinter (GMPrint), a specialized bio-ink (ColVivo), and sophisticated cell processing techniques, all designed to meet stringent FDA requirements for therapeutic manufacturing. Pre-clinical studies have shown the platform's efficacy in generating functional living tissues, positioning 3DBio Therapeutics at the forefront of personalized therapeutic solutions.
How much funding has 3DBio Therapeutics raised?
3DBio Therapeutics has raised a total of $20M across 1 funding round:
Other Financing Round
$20M
Other Financing Round (2020): $20M with participation from Western Technology Investment, BlueSeed Ventures, Alexandria Venture Investments, and Barer & Son Capital
Key Investors in 3DBio Therapeutics
Western Technology Investment
Western Technology Investment (WTI) is a venture debt provider that supports startups in financing their growth, often with a founder-friendly approach. They have a long history of capital provision across various innovation sectors since 1980.
BlueSeed Ventures
BlueSeed Ventures is an investor participating in the funding round for 3DBio Therapeutics. Further details on their investment focus are not publicly available.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc. (operating as Alexandria Venture Investments) is a real estate investment trust focused on properties for the life sciences industry, including R&D laboratories for biotech and pharmaceutical companies.
What's next for 3DBio Therapeutics?
With its recent major strategic investment, 3DBio Therapeutics is poised to accelerate its development and commercialization efforts. The substantial capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and potentially expand clinical trials. This strategic financing indicates strong investor confidence in the company's innovative approach to regenerative medicine and its potential to disrupt traditional therapeutic models, paving the way for significant market penetration and impact.
See full 3DBio Therapeutics company page
